Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus LESSINA 28.
ARANELLE vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive